Low high-density lipoprotein cholesterol is associated with impaired endothelial function in Asian Indians

Ethnicity and Disease

Volumn 15, Issue 4, 2005, Pages 555-561

  Packard, Kathleen A ^a   Majeed, Farhan ^b   Mohiuddin, Syed M ^c   Mooss, Aryan N ^c   Hilleman, Daniel E ^a,d   Arouni, Amy J ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Asian Indian; Endothelial function; Flow mediated dilation; High density lipoprotein cholesterol

Indexed keywords

GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASIAN; ASIAN AMERICAN; BRACHIAL ARTERY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM LESION; ETHNIC GROUP; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; INDIAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ASIAN AMERICANS; BRACHIAL ARTERY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPEREMIA; INDIA; MALE; MULTIVARIATE ANALYSIS; SEX FACTORS; TRIGLYCERIDES; UNITED STATES; VASODILATION;

EID: 27844541248     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 1992;70:945-949.
2. Miller GJ, Beckles GL, Byam NT, et al. Serum lipoprotein concentrations in relation to ethnic composition and urbanization in men and women of Trinidad, West Indies. Indian J Epidemiol. 1994;13:413-421.
3. Miller GJ, Kotecha S, Wilkinson WH, et al. Dietary and other characteristics relevant for coronary heart disease in men of Indian, West Indian, and European descent in London. Atherosclerosis. 1988;70(1-2):63-72.
4. Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India. J Am Coll Cardiol. 2001; 38:682-687.
5. Hoogeveen RC, Gambhir JK, Gambhir DS, et al. Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res. 2001;42: 631-638.
6. Dhawan J. Coronary heart disease in Asian Indians. Curr Opin Lipid. 1996;7:196-198.
7. Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein (a) as an independent risk factor for coronary artery disease in patients below 40 years of age. Indian Heart J. 2000; 52:411-415.
8. Enas EA, Dhawan J, Petkar S. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein(a). Indian Heart J. 1997; 49:25-34.
9. Vardan S, Mookherjee S, Vardan S, Sinha A. Special features of coronary heart disease in people of the Indian sub-continent. Indian Heart J. 1995;47:399-407.
10. Chuang CZ, Subramaniam PN, LeGardeur BY, Lopez A. Risk factors for coronary artery disease and levels of lipoprotein(a) and fat-soluble antioxidant vitamins in Asian Indians of USA. Indian Heart J. 1998;50:285-291.
11. Tai ES, Emmanuel SC, Chew SK, Tan BY, Tan CE. Isolated low HDL cholesterol. An insulin-resistant state only in the presence of fasting hypertriglyceridemia. Diabetes. 1999; 48:1088-1092.
12. Miller M, Rhyne J, Khatta M, Parekh H, Zeller K. Prevalence of the APOC3 promoter polymorphisms T-455C and C-482T in Asian-Indians. Am J Cardiol. 2001;87:220-221.
13. Yagalla MV, Hoerr SL, Song WO, Enas A, Garg A. Relationship of diet, abdominal obesity, and physical activity to plasma lipoprotein levels in Asian Indian physicians residing in the United States. J Am Diet Assoc. 1996;96:257-261.
14. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Ysuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48:343-353.
15. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101: 1899-1906.
16. Suwaido JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up on patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:958-964.
17. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
18. Halcox JPJ, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106: 653-658.
19. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol. 1999; 31:51-60.
20. Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb and Hemostasis. 2000;26:529-537.
21. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesteremia, and hypertension. J Clin Invest. 1993;92:652-662.
22. Perrault LP, Mahlberg F, Breugnot C, et al. Hypercholesteremia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. Arterioscler Thromb Vasc Biol. 2000;20: 728-736.
23. Uehata A, Lieberman EH, Gerhard MD, et al. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med. 1998;3:263-267.
24. Corretti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery vasodilation using high-frequency ultrasound. Am J Physiol. 1995;268:H1397-H1404.
25. Schnell GB, Robertson A, Houston D, Malley L, Anderson TJ. Impaired brachial artery endothelial function is not predicted by elevated triglycerides. J Am Coll Cardiol. 1999; 34:2038-2043.
26. Anderson TJ. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol. 1995;26: 1235-1241.
27. Paddu P, Paddu GM, Muscari A. HMG-CoA reductase inhibitors: is the endothelium the main target? Cardiology. 2001;95:9-13.
28. Wassman S, Ulrich L, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37: 1450-1457.
29. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis. 1998;137:197-203.
30. Maeso R, Aragoncillo P, Navarro-Cid J, et al. Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits. Gen Pharmacol. 2000;34:263-272.
31. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Aterioscler Thromb Vasc Biol. 2000;20:61-69.
32. Hamasaki S, Higano ST, Suwaidi JA, et al. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. Arterioscler Thromb Vasc Biol. 2000; 20:737-743.
33. Wang YX, Martin-McNulty B, Huw LY, et al. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 2002;162:23-31.
34. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162:179-185.
35. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT). Cardiol Res. 2001;52:290-298.
36. Evans M, Anderson RA, Graham J, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773-1779.
37. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995;26: 1615-1622.
38. Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis. 1998;138:229-235.
39. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
40. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1990;1044:275-283.
41. Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 1993;72:1103-1109.
42. Galle J, Ochslen M, Schollmeyer P, Wanner C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension. 1994; 23:556-564.
43. Genest J. Genetics and prevention: a new look at high-density lipoprotein cholesterol. Cardiol Rev. 2002;10:61-71.
44. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1991;68:1425-1430.
45. Zeiher AM, Schachinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Circulation. 1994;89:2525-2532.
46. Raitakari OT, Adams MR, Celermajer DS. Effect of Lp(a) on the early functional and structural changes of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;19(4):990-995.
47. Toikka JO, Ahotupa M, Viikari J, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999;147:133-138.
48. Zhang X, Zhao SP, Li XP, Gan M, Zhou QC. Endothelium-dependent and independent functions are impaired in patients with coronary heart disease. Atherosclerosis. 2000; 149:19-24.
49. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians. Heart. 1999;81:501-504.
50. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol, 1997;80: 831-835.
51. Meco JF, Vila R, Pujol R, et al. Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate. J Cardiovasc Pharmacol. 2001;38:250-258.
52. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
53. De Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation. 2002;105: 2159-2165.
54. Selwyn AP, Kinlay S, Libby P, et al. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997;95:5-7.